Needless to say, the biotech world has had a very difficult year. Even the biggest and the best companies, many of which trade cheaper than big pharmaceutical companies, have suffered as investors have fled. Much of the blame for the poor showing is the very shrill election year rhetoric from politicians over drug pricing, and while there is always an argument for lower prices, taking down an entire sector is extreme.
The XBI biotech index was up 13% over the past month, versus 5% for the S&P 500, and some on Wall Street contend that the political chatter and overhang worry is going away. It is also notable that at the recent party conventions there was little mention of drug pricing.
A new report from Wedbush focuses on upcoming catalysts for stocks in the firm’s coverage universe. We found four rated Outperform with monster potential upside to the posted price targets. All the companies will be presenting at the Wedbush Healthcare conference this month.
This company has big Phase 3 enrollment and results over the next year. Aimmune Therapeutics Inc. (NASDAQ: AIMT) is a clinical-stage biopharmaceutical company engaged in the development of desensitization treatments for peanut and other food allergies. The company’s Characterized Oral Desensitization Immunotherapy includes AR101, a product in Phase 3 registration trial for the treatment of peanut allergy in children and adults.
The Wedbush team note that the complete enrollment for the Phase 3 PALISADE trial and the data from the trial will be forthcoming. Needless to say, a positive result would be huge as peanut and other food allergy issues can be extremely dangerous. The enrollment should be completed this year and the results in the second half of 2017.
The Wedbush price target for the stock is a gigantic $48, and the Wall Street consensus target is $37.75. Shares closed most recently at $12.29.
This stock has been crushed over the past year and is offering a very solid entry point. Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutics to treat inflammatory and metabolic diseases. Its product pipeline includes CAT-1004, an oral small molecule that has completed Phase 1 clinical trials for the treatment of Duchenne muscular dystrophy.
Other clinicals include CAT-2054, which is in Phase 1 clinical trial for the treatment of hypercholesterolemia in patients for whom existing treatments are insufficient, and CAT-2003, which has completed Phase 2a trials to the treatment of patients with elevated triglycerides or hypertriglyceridemia. It is also developing CAT-4001, which is in preclinical stage for the treatment for severe, rare neurodegenerative diseases, such as Friedreich’s ataxia and amyotrophic lateral sclerosis.
The Wedbush team expects part B results from the Phase 1 and 2 CAT-1004 results for Duchenne muscular dystrophy by the end of this year.
The $17 Wedbush price objective compares with the consensus target of $16. The shares closed most recently at $4.06.